Aspen Neuroscience, Inc. Form SCHEDULE 13D — Nov 9, 2026
ARCH Venture entities and partners filed a Schedule 13D disclosing beneficial ownership of 3,754,922 shares of Aspen Neuroscience common stock, a 12.9% stake, following Aspen's IPO. Paul Berns separately reports 1,200,000 shares, or 4.1% of the class. The stake stems from five rounds of preferred stock purchases dating back to December 2018, plus a November 2, 2026 purchase of 1,333,333 shares at $15.00 per share from the IPO underwriters, with cumulative purchases totaling roughly $65 million across the three ARCH funds.
Key figures
- Shares Outstanding
- 29078600
- Total paid avf x
- $24,399,203.64
- Arch shares owned
- 3754922
- Ipo reverse split
- 1 for 9.8821
- Arch percent owned
- 12.9%
- Berns shares owned
- 1200000
- Lockup period days
- 180
- Total paid avf xiv
- $18,000,000.00
- Berns percent owned
- 4.1%
- Purchase date common
- 11/02/2026
- Purchase price common
- $15.00 per share
- Total paid avf x overage
- $22,715,335.19
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.